Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma

被引：0
|
作者：
Daniel M. Geynisman
Mauricio Burotto
Camillo Porta
Cristina Suarez
Maria T. Bourlon
Stephen Huo
Viviana Del Tejo
Ella X. Du
Xiaoran Yang
Keith A. Betts
Toni K. Choueiri
Bradley McGregor
机构：
[1] Fox Chase Cancer Center,Department of Hematology/Oncology
[2] Bradford Hill Clinical Research Center,Oncology Department
[3] University of Bari ‘A.Moro’ and Division of Oncology,Interdisciplinary Department of Medicine
[4] A.O.U. Consorziale Policlinico di Bari,Medical Oncology, Vall d’ Hebron Institute of Oncology (VHIO)
[5] Hospital Universitari Vall d’ Hebron,Department of Hemato
[6] Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,Oncology, Urologic Oncology Clinic
[7] Bristol Myers Squibb,Worldwide Health Economics and Outcomes Research
[8] Bristol Myers Squibb,US Market
[9] Analysis Group,US Medical Oncology
[10] Inc.,Health Economics and Outcomes Research
[11] Dana-Farber Cancer Institute,Department of Medical Oncology, Lank Center for Genitourinary Oncology
来源：
Clinical Drug Investigation | 2022年 / 42卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：611 / 622
页数：11
相关论文
共 50 条
  • [1] Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
    Geynisman, Daniel M.
    Burotto, Mauricio
    Porta, Camillo
    Suarez, Cristina
    Bourlon, Maria T.
    Huo, Stephen
    Del Tejo, Viviana
    Du, Ella X.
    Yang, Xiaoran
    Betts, Keith A.
    Choueiri, Toni K.
    McGregor, Bradley
    [J]. CLINICAL DRUG INVESTIGATION, 2022, 42 (07) : 611 - 622
  • [2] TEMPORAL TRENDS IN GRADE 3/4 ADVERSE EVENTS AND ASSOCIATED COSTS OF NIVOLUMAB PLUS CABOZANTINIB (N plus C) VERSUS SUNITINIB (S) FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC)
    Geynisman, D.
    McGregor, B.
    Burotto, M.
    Porta, C.
    Suarez, C.
    Bourlon, M. T.
    Stwalley, B.
    Du, E. X.
    Gu, C.
    Yang, X.
    Betts, K. A.
    Huo, S.
    Choueiri, T. K.
    [J]. VALUE IN HEALTH, 2021, 24 : S36 - S36
  • [3] Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma
    Geynisman, Daniel M.
    Du, Ella X.
    Yang, Xiaoran
    Sendhil, Selvam R.
    Tejo, Viviana Del
    Betts, Keith A.
    Huo, Stephen
    [J]. FUTURE ONCOLOGY, 2022, 18 (10) : 1219 - 1234
  • [4] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Escudier, B.
    Bourlon, M. T.
    Zurawski, B.
    Juarez, V. M. Oyervides
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Goh, J. C.
    Barrios, C.
    Richardet, M.
    Porta, C.
    Kowalyszyn, R.
    Feregrino, J. P.
    Zolnierek, J.
    Pook, D.
    Kessler, E. R.
    Tomita, Y.
    Mizuno, R.
    Bedke, J.
    Zhang, J.
    Maurer, M. A.
    Simsek, B.
    Ejzykowicz, F.
    Schwab, G. M.
    Apolo, A. B.
    Motzer, R. J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09): : 829 - 841
  • [5] GRADE 3/4 ADVERSE EVENT (AE) COSTS OF NIVOLUMAB PLUS IPILIMUMAB (N plus I) VERSUS NIVOLUMAB PLUS CABOZANTINIB (N plus C) AND PEMBROLIZUMAB PLUS AXITINIB (P plus A) FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC)
    McGregor, B.
    Geynisman, D.
    Burotto, M.
    Porta, C.
    Suarez, C.
    Bourlon, M. T.
    Stwalley, B.
    Du, E. X.
    Gu, C.
    Sendhil, S.
    Betts, K. A.
    Huo, S.
    Choueiri, T. K.
    [J]. VALUE IN HEALTH, 2021, 24 : S28 - S29
  • [6] Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma
    不详
    [J]. EUROPEAN UROLOGY, 2021, 80 (02) : 256 - 257
  • [7] Comparison of adverse event costs of nivolumab combined with ipilimumab versus sunitinib for previously untreated metastatic renal cell carcinoma
    Betts, Keith
    Yang, Shuo
    Du, Ella X.
    Johansen, Jennifer
    Rao, Sumati
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB plus IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SPAIN
    Polanco Sanchez, C.
    Gooden, K. M.
    May, J.
    Malcolm, B.
    Du, E. X.
    Yin, L.
    Betts, K.
    [J]. VALUE IN HEALTH, 2019, 22 : S458 - S458
  • [9] COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB plus IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SWITZERLAND
    Oniangue-Ndza, C.
    Gooden, K. M.
    May, J.
    Malcolm, B.
    Du, E. X.
    Yin, L.
    Betts, K. A.
    [J]. VALUE IN HEALTH, 2019, 22 : S457 - S457
  • [10] COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB plus IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN PORTUGAL
    Alves, D.
    Polanco Sanchez, C.
    Gooden, K. M.
    May, J.
    Malcolm, B.
    Du, E. X.
    Yin, L.
    Betts, K. A.
    [J]. VALUE IN HEALTH, 2019, 22 : S463 - S463
12345